(Q61967416)
Statements
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Activity of Oral AB1010 Administered at 2 Dose Levels to Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis (English)
0 references
June 2005
0 references
July 2007
0 references
35
0 references
18 year
0 references
60 year
0 references